Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 5/20 | 0.37 |
| ▸ | PDE9A | O76083 | 1/20 | 0.35 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17005290 | 0.87 | PDE9A (0.34) | PDE9AEGLN1JAK2JAK1 | |
| SCHEMBL81730 | 0.87 | SLC22A2 (0.40) | — | |
| SCHEMBL22986885 | 0.86 | TOP1 (0.40) | TOP1 | |
| SCHEMBL19348226 | 0.86 | KDM4E (0.37) | TOP1JAK2JAK1 | |
| SCHEMBL10290021 | 0.85 | TOP1 (0.37) | TOP1 | |
| SCHEMBL19348227 | 0.83 | LMNA (0.35) | TOP1 | |
| SCHEMBL19307794 | 0.83 | TOP1 (0.33) | TOP1 | |
| SCHEMBL21356944 | 0.81 | CYP2D6 (0.35) | TOP1 | |
| SCHEMBL22986883 | 0.81 | TOP1 (0.37) | TOP1 | |
| SCHEMBL19307799 | 0.80 | TOP1 (0.38) | TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232479-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232479-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | TOP1 670/4885PDE9A 4855/4885ERCC5 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.